Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Chloroquine for the 2019 novel coronavirus SARS-CoV-2

(2020) Philippe Colson et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

(2020) Peter Richardson et al.   LANCET

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

COVID-19: combining antiviral and anti-inflammatory treatments

(2020) Justin Stebbing et al.   LANCET INFECTIOUS DISEASES

A new coronavirus associated with human respiratory disease in China

(2020) Fan Wu et al.   NATURE

First Case of 2019 Novel Coronavirus in the United States

(2020) Michelle L. Holshue et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

(2020) Timothy P. Sheahan et al.   Nature Communications

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

(2020)   Nature Microbiology

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

(2020) Canrong Wu et al.   Acta Pharmaceutica Sinica B

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

(2020) Xueting Yao et al.   CLINICAL INFECTIOUS DISEASES

Teicoplanin: an alternative drug for the treatment of COVID-19?

(2020) Sophie Alexandra Baron et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

(2020) Philippe Gautret et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A Review of SARS-CoV-2 and the Ongoing Clinical Trials

(2020) Yung-Fang Tu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

(2020) Yeming Wang et al.   LANCET

Labs rush to study coronavirus in transgenic animals — some are in short supply

(2020) Ewen Callaway   NATURE

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

(2020) Zhenming Jin et al.   NATURE

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compassionate Use of Remdesivir for Patients with Severe Covid-19

(2020) Jonathan Grein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

(2020) Wenhao Dai et al.   SCIENCE

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

(2020) Yan Gao et al.   SCIENCE

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

(2020) Timothy P. Sheahan et al.   Science Translational Medicine

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

(2020) Hongzhou Lu   BioScience Trends

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

(2020) Jianjun Gao et al.   BioScience Trends

Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease

(2020) Brendan T Freitas et al.   ACS Infectious Diseases

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

(2020) Cynthia Liu et al.   ACS Central Science

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

(2020) Qingxian Cai et al.   Engineering

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

(2020) J.M. Molina et al.   MEDECINE ET MALADIES INFECTIEUSES

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

(2020) Mayla Gabriela Silva Borba et al.   JAMA Network Open

Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019

(2020) Stephan D. Fihn et al.   JAMA Network Open

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

(2014) Lisa Oestereich et al.   ANTIVIRAL RESEARCH

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study

(2014) Jaffar A. Al-Tawfiq et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

(2014) Ali S Omrani et al.   LANCET INFECTIOUS DISEASES

The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis

(2014) J. M. Lucas et al.   Cancer Discovery